Memory Treatment Centers at the forefront of Alzheimer's treatment innovation, as featured in the Wall Street Journal

Memory Treatment Centers neurologist, Jamie Plante and current Leqembi patient were interviewed by the Wall Street Journal to investigate availability of new Alzheimers treatments. With the recent FDA approval of Leqembi (Lecanemab) in February 2023, Memory Treatment Centers has been one of the first in the nation to administer such treatments.

Memory Treatment Centers is treating dozens of patients at two clinics in Florida with Leqembi and preparing for a surge in demand, said medical director W. Jamie Plante. The clinics are working with imaging centers and laboratories to screen patients, and plan to recruit more specialists and other staff, Dr. Plante said.

“Janet Engelbrecht, who was diagnosed with Alzheimer’s this year at age 58, has received five Leqembi infusions at a Memory Treatment Centers clinic in Bonita Springs. She paid about $1,500 out-of-pocket for each of the first few infusions, she said.

Ms. Engelbrecht, a real-estate agent who has stopped working because of her symptoms, said she couldn’t afford to keep that up. She now pays about $440 a session with financial assistance from Eisai. “I feel better every time I go,” Ms. Engelbrecht said.” Wall Street Journal

Click to see the full Wall Street Journal article

At Memory Treatment Centers, we are committed to providing hope and relief to individuals struggling with various forms of cognitive impairment, including Alzheimer’s Disease. Our goal is to help patients achieve better health and a higher quality of life. If you or a loved one are interested in exploring the possibility of receiving Leqembi treatment, we welcome new patients and are eager to assist you on your journey to improved well-being.